MARKET

CELC

CELC

Celcuity Inc
NASDAQ
107.19
-7.62
-6.64%
Opening 13:58 03/27 EDT
OPEN
112.90
PREV CLOSE
114.81
HIGH
114.62
LOW
105.90
VOLUME
430.62K
TURNOVER
--
52 WEEK HIGH
120.32
52 WEEK LOW
7.58
MARKET CAP
4.96B
P/E (TTM)
-28.3092
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Sticks to Their Hold Rating for Celcuity (CELC)
TipRanks · 7h ago
Celcuity’s Earnings Call: Big Data, Bigger Ambitions
TipRanks · 17h ago
Celcuity Buy Rating Backed by Strong Gedatolisib Data, Upcoming VIKTORIA-1 Catalyst, and Favorable Risk-Reward
TipRanks · 1d ago
Celcuity Is Maintained at Buy by Stifel
Dow Jones · 1d ago
Stifel Maintains Buy on Celcuity, Raises Price Target to $125
Benzinga · 1d ago
Celcuity price target raised to $141 from $108 at Craig-Hallum
TipRanks · 1d ago
Celcuity Price Target Maintained With a $122.00/Share by Needham
Dow Jones · 1d ago
Needham Reiterates Buy on Celcuity, Maintains $122 Price Target
Benzinga · 1d ago
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.